The Anti-MOG (Myelin Oligodendrocyte Glycoprotein) Antibodies Blood Test detects antibodies targeting MOG, a protein on the surface of myelin in the central nervous system. This test is used to investigate immune-mediated demyelinating disorders, including MOG antibody-associated disease (MOGAD). Testing is performed in a UKAS-accredited laboratory, with an optional GP consultation.

What is the Anti-MOG Antibodies Test?

Myelin Oligodendrocyte Glycoprotein (MOG) is a protein located on the outer surface of myelin sheaths that insulate nerve fibres in the brain, spinal cord, and optic nerves. In some individuals, the immune system produces antibodies against MOG, leading to inflammation and damage to myelin.

The Anti-MOG antibodies test is used to help differentiate MOG antibody-associated disease (MOGAD) from other neurological conditions such as:

• Multiple sclerosis (MS)
• Neuromyelitis optica spectrum disorders (NMOSD)
• Other inflammatory demyelinating diseases

This distinction is clinically important, as MOGAD differs in prognosis, treatment response, and relapse riskcompared to other demyelinating conditions.

At London Blood Tests, Anti-MOG antibodies are measured using validated cell-based assays, considered the gold standard for accuracy.

Benefits of the Anti-MOG Antibodies Test

1. Identifies MOG Antibody-Associated Disease (MOGAD)
   Confirms immune-mediated demyelination linked to MOG antibodies.
2. Differentiates from MS and NMOSD
   Supports accurate diagnosis and avoids misclassification.
3. Guides Treatment Decisions
   Influences choice and duration of immunotherapy.
4. Supports Prognosis Assessment
   Helps assess relapse risk and disease course.
5. Useful in Acute & Recurrent Neurological Symptoms
   Particularly valuable in optic neuritis and transverse myelitis.
6. High-Specificity Testing Method
   Uses cell-based assays for reliable detection.
7. Optional GP Consultation for Interpretation
   Results reviewed with a GP to guide referral or follow-up.

Why Do I Need an Anti-MOG Antibodies Test?

You may benefit from this test if you experience symptoms suggestive of inflammatory demyelinating disease, including:

• Sudden or recurrent vision loss (optic neuritis)
• Spinal cord inflammation (transverse myelitis)
• Limb weakness or numbness
• Balance or coordination problems
• Episodes of neurological symptoms with recovery

Testing is commonly recommended when:

• MRI findings are atypical for multiple sclerosis
• AQP4 (aquaporin-4) antibodies are negative
• Demyelinating symptoms occur in children or young adults

Because treatment strategies differ between conditions, identifying Anti-MOG antibodies supports precise neurological diagnosis.

How the Test Works

In-Clinic Testing at London Blood Tests

1. Book Your Appointment
• Online or phone booking
• No fasting required
2. Pre-Test Review
• Inform the clinician about neurological symptoms and prior imaging.
3. Sample Collection
• Venous blood sample collected by a trained phlebotomist
• Takes 5–10 minutes
4. Laboratory Analysis
• Anti-MOG antibodies analysed using cell-based assays in a UKAS-accredited laboratory
5. Quality Control
• Results validated before release
6. Results Delivery
• Results typically available within 7–10 business days
7. Optional GP Consultation
• Review results and discuss neurology referral if needed

At-Home Blood Draw (Home or Hotel Phlebotomy – UK-Wide)

1. Book a Phlebotomist Visit
• Convenient home or hotel appointment
2. Professional Collection
• Sample collected safely and discreetly
3. Secure Transport
• Sample couriered same day to the laboratory
4. Laboratory Testing
• Same analysis as clinic testing
5. Results & Follow-Up
• Results delivered online, GP review optional

Your Anti-MOG Antibodies Results – Explained

Results are typically reported as positive or negative, sometimes with a titre.

Interpretation:

• Positive Anti-MOG antibodies: supports diagnosis of MOGAD
• Negative Anti-MOG antibodies: MOG-related disease less likely

Important notes:

• Antibody levels may fluctuate over time
• Results must be interpreted alongside clinical symptoms, MRI findings, and other antibody tests
• A positive result does not replace neurological assessment